299 related articles for article (PubMed ID: 28947015)
1. Response to omalizumab in patients with severe allergic asthma: A real-life study.
Zierau L; Walsted ES; Thomsen SF; Backer V
Respir Med; 2017 Oct; 131():109-113. PubMed ID: 28947015
[TBL] [Abstract][Full Text] [Related]
2. Real-life efficacy and safety of omalizumab in Portuguese patients with persistent uncontrolled asthma.
Pereira Barbosa M; Bugalho de Almeida A; Pereira C; Chen CW; Georgiou P; Peachey G;
Rev Port Pneumol (2006); 2015; 21(3):151-6. PubMed ID: 25926246
[TBL] [Abstract][Full Text] [Related]
3. Predictors of response to therapy with omalizumab in patients with severe allergic asthma - a real life study.
Kallieri M; Papaioannou AI; Papathanasiou E; Ntontsi P; Papiris S; Loukides S
Postgrad Med; 2017 Aug; 129(6):598-604. PubMed ID: 28427296
[TBL] [Abstract][Full Text] [Related]
4. Omalizumab lowers asthma exacerbations, oral corticosteroid intake and blood eosinophils: Results of a 5-YEAR single-centre observational study.
Pelaia C; Calabrese C; Barbuto S; Busceti MT; Preianò M; Gallelli L; Savino R; Vatrella A; Pelaia G
Pulm Pharmacol Ther; 2019 Feb; 54():25-30. PubMed ID: 30414440
[TBL] [Abstract][Full Text] [Related]
5. Omalizumab modulates bronchial reticular basement membrane thickness and eosinophil infiltration in severe persistent allergic asthma patients.
Riccio AM; Dal Negro RW; Micheletto C; De Ferrari L; Folli C; Chiappori A; Canonica GW
Int J Immunopathol Pharmacol; 2012; 25(2):475-84. PubMed ID: 22697079
[TBL] [Abstract][Full Text] [Related]
6. Longterm clinical outcomes of omalizumab therapy in severe allergic asthma: Study of efficacy and safety.
Mansur AH; Srivastava S; Mitchell V; Sullivan J; Kasujee I
Respir Med; 2017 Mar; 124():36-43. PubMed ID: 28284319
[TBL] [Abstract][Full Text] [Related]
7. A randomized multicenter study evaluating Xolair persistence of response after long-term therapy.
Ledford D; Busse W; Trzaskoma B; Omachi TA; Rosén K; Chipps BE; Luskin AT; Solari PG
J Allergy Clin Immunol; 2017 Jul; 140(1):162-169.e2. PubMed ID: 27826098
[TBL] [Abstract][Full Text] [Related]
8. Effectiveness of Omalizumab in Severe Allergic Asthma and Nasal Polyposis: A Real-Life Study.
Tiotiu A; Oster JP; Roux PR; Nguyen Thi PL; Peiffer G; Bonniaud P; Dalphin JC; de Blay F
J Investig Allergol Clin Immunol; 2020; 30(1):49-57. PubMed ID: 30931917
[TBL] [Abstract][Full Text] [Related]
9. The Long-Term Effectiveness and Safety of Omalizumab on Patient- and Physician-Reported Asthma Control: A Three-Year, Real-Life Observational Study.
Schreiber J; Schwab Sauerbeck I; Mailänder C
Adv Ther; 2020 Jan; 37(1):353-363. PubMed ID: 31741282
[TBL] [Abstract][Full Text] [Related]
10. Cost-effectiveness of omalizumab in real world uncontrolled allergic asthma patients.
Arrobas A; Barbosa MP; Rabiais S; Vandewalle B; Félix J
Pulmonology; 2021; 27(2):124-133. PubMed ID: 32247710
[TBL] [Abstract][Full Text] [Related]
11. The clinical benefit of mepolizumab replacing omalizumab in uncontrolled severe eosinophilic asthma.
Chapman KR; Albers FC; Chipps B; Muñoz X; Devouassoux G; Bergna M; Galkin D; Azmi J; Mouneimne D; Price RG; Liu MC
Allergy; 2019 Sep; 74(9):1716-1726. PubMed ID: 31049972
[TBL] [Abstract][Full Text] [Related]
12. "Real-life" effectiveness of omalizumab in patients with severe persistent allergic asthma: The PERSIST study.
Brusselle G; Michils A; Louis R; Dupont L; Van de Maele B; Delobbe A; Pilette C; Lee CS; Gurdain S; Vancayzeele S; Lecomte P; Hermans C; MacDonald K; Song M; Abraham I
Respir Med; 2009 Nov; 103(11):1633-42. PubMed ID: 19619998
[TBL] [Abstract][Full Text] [Related]
13. Omalizumab effectiveness in patients with severe allergic asthma according to blood eosinophil count: the STELLAIR study.
Humbert M; Taillé C; Mala L; Le Gros V; Just J; Molimard M;
Eur Respir J; 2018 May; 51(5):. PubMed ID: 29545284
[TBL] [Abstract][Full Text] [Related]
14. Higher blood eosinophil levels after omalizumab treatment may be associated with poorer asthma outcomes.
Sposato B; Scalese M; Milanese M; Masieri S; Cavaliere C; Latorre M; Scichilone N; Ricci A; Cresti A; Santus P; Olivieri C; Perrella A; Rogliani P; Paggiaro P;
J Allergy Clin Immunol Pract; 2019; 7(5):1643-1646. PubMed ID: 30898690
[No Abstract] [Full Text] [Related]
15. The significance of eosinophil and eosinophil lymphocyte ratio (ELR) in predicting response to omalizumab treatment in patients with severe allergic asthma.
Özgen H; Tepetam FM; Bulut İ; Örçen C
Tuberk Toraks; 2021 Mar; 69(1):39-48. PubMed ID: 33853304
[TBL] [Abstract][Full Text] [Related]
16. Association of upper and lower airway eosinophilic inflammation with response to omalizumab in patients with severe asthma.
Kurokawa M; Koya T; Takeuchi H; Hayashi M; Sakagami T; Ishioka K; Gon Y; Hasegawa T; Kikuchi T
J Asthma; 2020 Jan; 57(1):71-78. PubMed ID: 30489179
[No Abstract] [Full Text] [Related]
17. Baseline serum CXCL10 and IL-12 levels may predict severe asthmatics' responsiveness to omalizumab.
Suzukawa M; Matsumoto H; Ohshima N; Tashimo H; Asari I; Tajiri T; Niimi A; Nagase H; Matsui H; Kobayashi N; Shoji S; Ohta K
Respir Med; 2018 Jan; 134():95-102. PubMed ID: 29413515
[TBL] [Abstract][Full Text] [Related]
18. Baseline asthma burden, comorbidities, and biomarkers in omalizumab-treated patients in PROSPERO.
Chipps BE; Zeiger RS; Luskin AT; Busse WW; Trzaskoma BL; Antonova EN; Pazwash H; Limb SL; Solari PG; Griffin NM; Casale TB
Ann Allergy Asthma Immunol; 2017 Dec; 119(6):524-532.e2. PubMed ID: 29054589
[TBL] [Abstract][Full Text] [Related]
19. The effect of omalizumab on eosinophilic inflammation of the respiratory tract in patients with allergic asthma.
Kupryś-Lipińska I; Molińska K; Kuna P
Pneumonol Alergol Pol; 2016; 84(4):232-43. PubMed ID: 27435350
[TBL] [Abstract][Full Text] [Related]
20. Utility of serum periostin and free IgE levels in evaluating responsiveness to omalizumab in patients with severe asthma.
Tajiri T; Matsumoto H; Gon Y; Ito R; Hashimoto S; Izuhara K; Suzukawa M; Ohta K; Ono J; Ohta S; Ito I; Oguma T; Inoue H; Iwata T; Kanemitsu Y; Nagasaki T; Niimi A; Mishima M
Allergy; 2016 Oct; 71(10):1472-9. PubMed ID: 27113353
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]